Results 181 to 190 of about 28,966 (201)
Some of the next articles are maybe not open access.
2014
Hyperlipidemia is an important public health problem with increased incidence and prevalence worldwide. Current clinical biomarkers, triglyceride, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol lack the necessary specificity and sensitivity and only increase significantly after serious dyslipidemia ...
Hua Miao +4 more
openaire +2 more sources
Hyperlipidemia is an important public health problem with increased incidence and prevalence worldwide. Current clinical biomarkers, triglyceride, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol lack the necessary specificity and sensitivity and only increase significantly after serious dyslipidemia ...
Hua Miao +4 more
openaire +2 more sources
Expert Review of Pharmacoeconomics & Outcomes Research, 2003
Dyslipidemia has been recognized as an important risk-factor for the development of cardiovascular disease. The current, available therapies of dyslipidemia, their effectiveness, costs, cost-effectiveness and healthcare implications are discussed. At the present time, the lipid-lowering therapies are dominated by statins.
Hanna Zowall, Steven A. Grover
openaire +3 more sources
Dyslipidemia has been recognized as an important risk-factor for the development of cardiovascular disease. The current, available therapies of dyslipidemia, their effectiveness, costs, cost-effectiveness and healthcare implications are discussed. At the present time, the lipid-lowering therapies are dominated by statins.
Hanna Zowall, Steven A. Grover
openaire +3 more sources
American Journal of Health-System Pharmacy, 2010
The efficacy and safety of phytosterols for the management of dyslipidemia are reviewed.Phytosterols have been evaluated in over 40 clinical trials. The incorporation of 2 g of phytosterols daily into margarine, mayonnaise, orange juice, olive oil, low-fat milk, yogurt, and tablets is associated with significant reductions in low-density-lipoprotein ...
Monica M. Gehret, Jennifer M. Malinowski
openaire +3 more sources
The efficacy and safety of phytosterols for the management of dyslipidemia are reviewed.Phytosterols have been evaluated in over 40 clinical trials. The incorporation of 2 g of phytosterols daily into margarine, mayonnaise, orange juice, olive oil, low-fat milk, yogurt, and tablets is associated with significant reductions in low-density-lipoprotein ...
Monica M. Gehret, Jennifer M. Malinowski
openaire +3 more sources
Endocrine Practice, 1996
To summarize recommended treatment strategies for various dyslipidemias.The basic pathways of lipoprotein metabolism are reviewed, and the potential for interventional alterations to correct specific dyslipidemias is outlined. Guidelines for treatment based on published clinical trials, including the consensus report of the National Cholesterol ...
openaire +3 more sources
To summarize recommended treatment strategies for various dyslipidemias.The basic pathways of lipoprotein metabolism are reviewed, and the potential for interventional alterations to correct specific dyslipidemias is outlined. Guidelines for treatment based on published clinical trials, including the consensus report of the National Cholesterol ...
openaire +3 more sources
Heart Disease, 2002
Dyslipidemia is recognized as a significant risk factor for atherosclerotic disease. There has been a great deal of progress in the detection and management of dyslipidemia, but challenges remain, including whether to treat children, adolescents, and the elderly.
openaire +3 more sources
Dyslipidemia is recognized as a significant risk factor for atherosclerotic disease. There has been a great deal of progress in the detection and management of dyslipidemia, but challenges remain, including whether to treat children, adolescents, and the elderly.
openaire +3 more sources
Metabolism, 2014
Diabetic dyslipidemia is characterized by elevated fasting and postprandial triglycerides, low HDL-cholesterol, elevated LDL-cholesterol and the predominance of small dense LDL particles. These lipid changes represent the major link between diabetes and the increased cardiovascular risk of diabetic patients.
Liya, Wu, Klaus G, Parhofer
openaire +2 more sources
Diabetic dyslipidemia is characterized by elevated fasting and postprandial triglycerides, low HDL-cholesterol, elevated LDL-cholesterol and the predominance of small dense LDL particles. These lipid changes represent the major link between diabetes and the increased cardiovascular risk of diabetic patients.
Liya, Wu, Klaus G, Parhofer
openaire +2 more sources
Hypercholesterolemia and dyslipidemia
Current Treatment Options in Cardiovascular Medicine, 2000Disorders of cholesterol and lipoprotein metabolism are at the heart of atherosclerosis and coronary artery disease (CAD). CAD, however, is a metabolic disorder that involves a complex interaction between genetic susceptibility and environmental conditions.
openaire +3 more sources
The American Journal of Medicine, 2002
The 2 principal approaches to management of dyslipidemias are lifestyle intervention and lipid-modifying drug therapy. Recent revisions to the American Heart Association's dietary guidelines for reducing cardiovascular disease emphasize an overall healthy eating pattern and maintenance of appropriate body weight, together with achieving a desirable ...
openaire +3 more sources
The 2 principal approaches to management of dyslipidemias are lifestyle intervention and lipid-modifying drug therapy. Recent revisions to the American Heart Association's dietary guidelines for reducing cardiovascular disease emphasize an overall healthy eating pattern and maintenance of appropriate body weight, together with achieving a desirable ...
openaire +3 more sources
Steroids, 2012
Life-long apolipoprotein lipid metabolic dysfunction in women with PCOS exaggerates the risk for cardiovascular disease (CVD) with aging. The dysfunction has involved insulin resistance (IR), which occurs in most women with PCOS. Women with PCOS have androgen excess, IR, variable amounts of estrogen exposure, and many environmental factors, all of ...
openaire +3 more sources
Life-long apolipoprotein lipid metabolic dysfunction in women with PCOS exaggerates the risk for cardiovascular disease (CVD) with aging. The dysfunction has involved insulin resistance (IR), which occurs in most women with PCOS. Women with PCOS have androgen excess, IR, variable amounts of estrogen exposure, and many environmental factors, all of ...
openaire +3 more sources
2018
Not only a risk factor and predictor of future cardiovascular events, dyslipidemia play an important role in various steps of cardiovascular diseases. This puts the management of dyslipidemia on highlights and justifies various guidelines and recommendations on the matter.
openaire +2 more sources
Not only a risk factor and predictor of future cardiovascular events, dyslipidemia play an important role in various steps of cardiovascular diseases. This puts the management of dyslipidemia on highlights and justifies various guidelines and recommendations on the matter.
openaire +2 more sources